Fixed-dose darunavir/cobicistat in pregnancy of HIV-infected women, pharmacokinetic concerns

被引：2
作者：
Dash, Prasanta K. [1 ]
Boix, Vicente [2 ,3 ]
机构：
[1] Univ Nebraska Med Ctr, Coll Med, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA
[2] Hosp Gen Univ Alicante, ISABIAL, Unit Infect Dis, Alicante, Spain
[3] Univ Miguel Hernandez, Dept Med Clin, Elche, Spain
来源：
AIDS | 2021年 / 35卷 / 08期
关键词：
IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEASE; PHARMACODYNAMICS; COBICISTAT; DARUNAVIR; GS-9350;
D O I：
10.1097/QAD.0000000000002886
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：1301 / 1303
页数：3
相关论文
共 50 条
  • [21] Abacavir/Lamivudine Fixed-Dose Combination With Ritonavir-Boosted Darunavir: A Safe and Efficacious Regimen for HIV Therapy
    Trottier, Benoit
    Machouf, Nima
    Thomas, Rejean
    Gallant, Serge
    Longpre, Daniele
    Vezina, Sylvie
    Boissonnault, Michel
    Lavoie, Stephane
    Legault, Danielle
    Dion, Harold
    Vinh Kim Nguyen
    HIV CLINICAL TRIALS, 2012, 13 (06): : 335 - 342
  • [22] Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants
    Feng, Hwa-Ping
    Guo, Zifang
    Fandozzi, Christine
    Panebianco, Deborah
    Caro, Luzelena
    Wolford, Dennis
    Dreyer, Daniel R.
    Valesky, Robert
    Martinho, Monika
    Rizk, Matthew L.
    Iwamoto, Marian
    Yeh, Wendy W.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2019, 8 (07): : 952 - 961
  • [23] Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge
    Elliot, Emilie R.
    Amara, Alieu
    Pagani, Nicole
    Else, Laura
    Moyle, Graeme
    Schoolmeesters, Alex
    Higgs, Chris
    Khoo, Saye
    Boffito, Marta
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017, 72 (07) : 2035 - 2041
  • [24] Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
    Mulligan, Nikki
    Schalkwijk, Stein
    Best, Brookie M.
    Colbers, Angela
    Wang, Jiajia
    Capparelli, Edmund V.
    Molto, Jose
    Stek, Alice M.
    Taylor, Graham
    Smith, Elizabeth
    Tenorio, Carmen Hidalgo
    Chakhtoura, Nahida
    van Kasteren, Marjo
    Fletcher, Courtney V.
    Mirochnick, Mark
    Burger, David
    FRONTIERS IN PHARMACOLOGY, 2016, 7
  • [25] Pharmacokinetic interaction between nevirapine and darunavir with low-dose ritonavir in HIV-1-infected patients
    Sekar, Vanitha
    Lefebvre, Eric
    Marien, Kris
    De Pauw, Martine
    Vangeneugden, Tony
    Pozniak, Anton
    Hoetelmans, Richard M. W.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (01) : 116 - 119
  • [26] HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
    Harris, Marianne
    Ganase, Bruce
    Watson, Birgit
    Harrigan, P. Richard
    Montaner, Julio S. G.
    Hull, Mark W.
    AIDS RESEARCH AND THERAPY, 2017, 14 : 1 - 9
  • [27] Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults
    Sandy Van Hemelryck
    Erika Van Landuyt
    Jay Ariyawansa
    Martyn Palmer
    Martine J. C. Kothe
    Caroline Pollefliet
    AAPS Open, 10 (1)
  • [28] HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study
    Marianne Harris
    Bruce Ganase
    Birgit Watson
    P. Richard Harrigan
    Julio S. G. Montaner
    Mark W. Hull
    AIDS Research and Therapy, 14
  • [29] Darunavir, promising option in therapy multi-experience HIV-infected patients
    Olczak, Anita
    HIV & AIDS REVIEW, 2008, 7 (01): : 5 - 9
  • [30] Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach
    Dailly, E.
    Raffi, F.
    Perre, P.
    Martin, J.
    Deslandes, G.
    Jolliet, P.
    HIV MEDICINE, 2009, 10 (09) : 586 - 589
12345